

**Freedom of Information Act 2000 - Request Reference FoI/23/233**

**Drugs Treatment**

**Information Requested:**

I have a Freedom of information query. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs :

- **Aubagio (teriflunomide) - 5**
- **Avonex (interferon beta-1a) 0**
- **Betaferon (interferon beta-1b) 0**
- **Brabio (glatiramer acetate) 4**
- **Copaxone (glatiramer acetate) 0**
- **Extavia (beta interferon-1b) 0**
- **Gilenya (fingolimod) 45**
- **Lemtrada (alemtuzumab) 10**
- **Kesimpta (ofatumumab) 14**
- **Mavenclad (cladribine) 16**
- **Mayzent (siponimod) 27**
- **Ocrevus (ocrelizumab) 121**
- **Plegridy (peginterferon beta-1a) 5**
- **Ponvory (ponesimod) 1**
- **Rebif (beta interferon-1a) 0**
- **Tecfidera (dimethyl fumarate) 119**
- **Tysabri (natalizumab) 87**
- **Tysabri (natalizumab) pre-filled syringes ONLY 74**
- **Vumerity (diroximel fumarate) 5**
- **Zeposia (ozanimod) 1**

It would also be very helpful if you could advise how many hospital patients registered with your trust/health board have a primary or secondary diagnosis for the following conditions:

- **Multiple sclerosis (any type)**
- **Relapsing remitting multiple sclerosis (RRMS)**
- **Primary progressive multiple sclerosis (PPMS)**
- **Secondary progressive multiple sclerosis (SPMS)**

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under our Section 16 obligation we can advise that there are 384 distinct patients coded with a diagnosis of Multiple Sclerosis following an inpatient/day case stay, however the UHB is unable to identify the MS variant. This data is from 1<sup>st</sup> April 2022 to 31<sup>st</sup> March 2023.